bionomics.com.au (BNOX) - Cash Funds per Share

Bionomics Ltd. - graphic logo of issuer BNOX

Cash per share monitoring for Bionomics Limited (BNOX) demonstrates the impact of strict FDA control and high patent costs, with the metric holding around 0.47. Bionomics Limited (BNOX) is developing advanced therapies for PTSD and anxiety without the risk of dependence. Business stability is ensured by the neutral status of biomedicine, which minimizes the impact of global political upheavals on operational activities.

Bionomics Ltd. (BNOX) Cash Funds per Share: for the period 07/04/2022 - 12/24/2024

Analytical breakdowns for Bionomics Limited

- market price and analyst price targets:
- market capitalization indicators:
- cash availability and cash flow indicators:
Comprehensive company analysis:BNOX Bionomics
Product sample of Bionomics

Bionomics Limited is optimizing costs by outsourcing the synthesis of neuro-drugs to third-party contractors in the US and Australia. Cash per share determines the portion of liquid capital attributable to a single security. This metric allows for the tracking of equity dilution during new issuances and the actual margin of safety. It is critical for investors to correlate this reserve with the cash burn rate. The cash per share trend over the period reveals the balance between financial stability and investment activity.